Day: May 8, 2020

Lerøy Seafood Group ASA presenterer resultater for 1. kvartal 2020 torsdag den 14. mai 2020.  For å redusere risikoen for spredning av koronaviruset (Covid-19), og i tråd med myndighetenes anbefalinger om å begrense fysiske møter, vil presentasjonen holdes direkte på norsk webcast klokken 08.00 på www.leroyseafood.com. Det vil være mulig å stille spørsmål i webcasten som besvares fortløpende etter presentasjonen. Engelsk webcast vil være tilgjengelig fra klokken 12.00 på www.leroyseafood.com.Kvartalsrapporten og presentasjonen vil bli offentliggjort kl. 06.30.Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

NOT FOR DISTRIBUTION IN THE U.S.A. OR OVER U.S. WIRE SERVICESMISSISSAUGA, Ontario, May 08, 2020 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX: KPT) announced today that the Board of Directors has declared a quarterly dividend of $0.18 per common share, payable on July 13, 2020 to shareholders of record at the close of business on June 26, 2020, subject to applicable law.The dividends paid are designated as “eligible” dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation.The dividend is being declared in connection with the declaration of a corresponding quarterly distribution by Kruger Products L.P. (“KPLP”) in which KP Tissue holds a limited partnership interest.Dividend Reinvestment PlanThe Corporation has a Dividend Reinvestment Plan under which eligible...

NON DESTINÉ À LA PUBLICATION AUX ÉTATS-UNIS NI AUX AGENCES DE TRANSMISSION AMÉRICAINESMISSISSAUGA, Ontario, 08 mai 2020 (GLOBE NEWSWIRE) — Papiers Tissu KP inc. (TSX : KPT) (« PTKP »), a annoncé aujourd’hui que son conseil d’administration a déclaré un dividende trimestriel de 0,18 $ par action ordinaire. Ce dividende sera payable le 13 juillet 2020 aux actionnaires inscrits à la fermeture des bureaux le 26 juin 2020, sous réserve des lois applicables.Les dividendes versés pourront être considérés comme « admissibles » aux fins de la Loi de l’impôt sur le revenu (Canada) et de toute loi provinciale ou territoriale semblable.Ce dividende est déclaré en lien avec l’annonce d’une distribution trimestrielle correspondante faite par Produits Kruger S.E.C (« PK S.E.C. ») une société dans laquelle PTKP détient une participation de commanditaire.Plan...

ALPHARETTA, Ga., May 08, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020.“Our team remains focused on progressing our programs as we navigate the evolving business and regulatory environment,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer. “We are committed to advancing our first product candidate, XIPERE™, to the U.S. regulatory finish line as quickly as possible to maximize its commercial potential. Our Investigational New Drug application remains on track for submission in mid-2020 for CLS-AX (axitinib injectable suspension) in wet age-related macular...

SPOKANE, Wash., May 08, 2020 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today reported net income attributable to Avista Corp. shareholders of $48.4 million, or $0.72 per diluted share for the first quarter of 2020, compared to $115.8 million, or $1.76 per diluted share for the first quarter of 2019.“Our primary focus is the safety of our customers and employees while providing reliable energy service during this difficult and uncertain time. We know that many people are hurting, businesses are hard hit and communities are challenged as a result of the COVID-19 pandemic and we want to express our deepest sympathies to everyone who is suffering unprecedented hardships during the COVID-19 pandemic,” said Dennis Vermillion, president and chief executive officer of Avista Corp.“Even with the challenges we faced this quarter,...

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May 12-14, 2020. Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 11:00 AM Eastern Time on Thursday, May 14. A live audio webcast will be available on the “Events & Presentations” section of the FibroGen website at www.fibrogen.com. A replay of the fireside chat will be available for 30 days.About FibroGenFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines...

ATLANTA, May 08, 2020 (GLOBE NEWSWIRE) — EVO Payments, Inc. (NASDAQ: EVOP) (“EVO” or the “Company”) today announced its first quarter 2020 financial results.  For the first quarter ended March 31, 2020, reported revenue of $111.2 million was flat compared to $111.5 million in the prior year.  On a currency neutral basis, reported revenue for the first quarter increased 1.5%.  On a GAAP basis for the quarter ended March 31, 2020, the Company recognized a net loss of $13.6 million, an improvement of 29% compared to the prior year.  Adjusted EBITDA increased 3% to $31.5 million for the quarter, and on a currency neutral basis, adjusted EBITDA grew 6% over the prior year. “While the last month of the quarter was adversely impacted by COVID-19, the full effect of the economic disruption from the virus will manifest in the second quarter. ...

WALTHAM, Mass., May 08, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format.Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at http://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that...

CICERO, Ill., May 08, 2020 (GLOBE NEWSWIRE) — Broadwind (NASDAQ: BWEN), a diversified precision manufacturer of specialized components and solutions serving global industries, today announced results for the first quarter 2020.1Q20 HIGHLIGHTSTotal revenue of $48.6 million (+17% y/y)Total gross margin of 12.7% (+420 bps y/y)Total net income of $1.0 million, or $0.06 per basic shareTotal non-GAAP adjusted EBITDA of $3.6 million (+$1.9 million y/y)Total orders of $33.8 million (+41% y/y)Total backlog of $127.4 million (+57% y/y)Total cash and availability of $19.0 million (+$11.5 million y/y)FULL-YEAR 2020 MANAGEMENT OUTLOOKWithdrawing full-year 2020 guidance and assumptions due to potential impact from COVID-19Implementing measures to reduce operating expenses and discretionary capital expendituresFor the three months ended March...

GAITHERSBURG, Md., May 08, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.